Fingerprint
Dive into the research topics of 'PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab
Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J. Feinstein, Arman Qamar, Parag H. Joshi, Kristopher J. Swiger, Kathleen Byrne, Renato Quispe, Steven R. Jones, Roger S. Blumenthal, Seth S. Martin
Research output: Contribution to journal › Review article › peer-review
7
Scopus
citations